200,000+ products from a single source!
sales@angenechem.com
133040-01-4 | 2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (αE)-
CAS No: 133040-01-4 Catalog No: AG0011JO MDL No:
Product Description
Catalog Number:
AG0011JO
Chemical Name:
2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (αE)-
CAS Number:
133040-01-4
Molecular Formula:
C23H24N2O4S
Molecular Weight:
424.5127
SMILES:
CCCCc1ncc(n1Cc1ccc(cc1)C(=O)O)/C=C(/C(=O)O)\Cc1cccs1
Literature
| Title | Journal |
|---|---|
| Determination of eprosartan mesylate and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromatographic methods. | Journal of chromatographic science 20120901 |
| Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials. | European journal of clinical pharmacology 20120201 |
| Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. | Journal of clinical hypertension (Greenwich, Conn.) 20120201 |
| [The use of melatonin for correction of sleep disturbances in assembly-line shift workers with arterial hypertension]. | Klinicheskaia meditsina 20120101 |
| Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population: preliminary report of the observational POWER study. | Vascular health and risk management 20120101 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
| The effect of eprosartan on reflex sympathetic activation in sodium restricted patients with essential hypertension. | Journal of the American Society of Hypertension : JASH 20110101 |
| Liquid chromatographic method for the simultaneous determination of eprosartan and hydrochlorothiazide in tablets and human plasma. | Journal of AOAC International 20110101 |
| Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study. | Vascular health and risk management 20110101 |
| Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective. | Bioorganic & medicinal chemistry 20101215 |
| A predictive ligand-based Bayesian model for human drug-induced liver injury. | Drug metabolism and disposition: the biological fate of chemicals 20101201 |
| [Adjustment of antihypertensive therapy to a generic eprosartan preparation. Results of a non-interventional study]. | MMW Fortschritte der Medizin 20101014 |
| Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). | Advances in therapy 20100601 |
| Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. | European journal of heart failure 20100401 |
| Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. | Biopharmaceutics & drug disposition 20100301 |
| Characterization of a novel impurity in bulk drug eprosartan by ESI/MS(n) and NMR. | Journal of pharmaceutical and biomedical analysis 20100205 |
| Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction. | Cardiovascular drugs and therapy 20100201 |
| Development and validation of a high-performance liquid chromatographic method for determination of eprosartan in bulk drug and tablets. | Journal of AOAC International 20100101 |
| Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20091201 |
| Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090901 |
| Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. | The Journal of pharmacology and experimental therapeutics 20090601 |
| Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats. | Hypertension (Dallas, Tex. : 1979) 20090501 |
| Angiotensin receptor blockers and secondary stroke prevention: the MOSES study. | Expert review of cardiovascular therapy 20090501 |
| Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20090301 |
| Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study. | Drugs & aging 20090101 |
| [The use of melaxen in combined therapy of arterial hypertension in subjects occupied in assembly line production]. | Klinicheskaia meditsina 20090101 |
| Eprosartan: a review of its use in hypertension. | Drugs 20090101 |
| Clinical profile of eprosartan: a different angiotensin II receptor blocker. | Cardiovascular & hematological agents in medicinal chemistry 20081001 |
| Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. | Journal of hypertension 20080801 |
| Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension. | Journal of human hypertension 20080701 |
| Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans. | British journal of clinical pharmacology 20080601 |
| Spectral and polarographic determination of eprosartan. Kinetic studies of the oxidation of eprosartan using a platinum electrode. | Die Pharmazie 20080601 |
| Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. | Hypertension (Dallas, Tex. : 1979) 20080301 |
| Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method. | Journal of separation science 20080301 |
| Selenosartans: novel selenophene analogues of milfasartan and eprosartan. | Bioorganic & medicinal chemistry letters 20080201 |
| Effectiveness of eprosartan in diabetic hypertensive patients. | European journal of internal medicine 20080101 |
| Comparison of monotherapy versus combination antihypertensive therapy in elderly patients with essential hypertension. | Angiology 20080101 |
| [Effect of antihypertensive drugs of various pharmacological groups on reaction of arterial pressure under conditions of stree testing. Part II. Value of various strategies of potentiation of systemic vasodilatation]. | Kardiologiia 20080101 |
| [Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome]. | Klinicheskaia meditsina 20080101 |
| Eprosartan in the primary prevention of cardiac allograft vascular disease: a double-blind prospectively randomized study using intravascular ultrasound. | The Journal of international medical research 20080101 |
| Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline. | Expert review of cardiovascular therapy 20071101 |
| Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. | Current medical research and opinion 20071101 |
| Angiotensin blockade with eprosartan: vascular and functional implications. | Current medical research and opinion 20071101 |
| Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature. | Current medical research and opinion 20071101 |
| Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines? | Current medical research and opinion 20071101 |
| Pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers of different gender. | Die Pharmazie 20071001 |
| An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. | Life sciences 20070802 |
| Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors. | Acta cardiologica 20070801 |
| Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients. | Journal of thrombosis and haemostasis : JTH 20070701 |
| Determination of eprosartan in human plasma and urine by LC/MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070615 |
| [Role of the renin-angiotensin system on the sympathetic response induced by the cold pressor test in humans]. | Investigacion clinica 20070601 |
| Small artery structure adapts to vasodilatation rather than to blood pressure during antihypertensive treatment. | Journal of hypertension 20070501 |
| Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients. | Fundamental & clinical pharmacology 20070401 |
| Effect of AT(1) angiotensin II receptor antagonists on the sympathetic response to a cold pressor test in healthy volunteers. | American journal of therapeutics 20070101 |
| Eprosartan in secondary prevention of stroke: the economic evidence. | Cardiovascular journal of Africa 20070101 |
| [The effectiveness of eprosartan in patients with chronic glomerulonephritis]. | Klinicheskaia meditsina 20070101 |
| Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. | The open cardiovascular medicine journal 20070101 |
| [Stress-associated hypertension in the work place: results of the STARLET project]. | Deutsche medizinische Wochenschrift (1946) 20061117 |
| [Not all antihypertensive agents protect equally well]. | MMW Fortschritte der Medizin 20060817 |
| Validation of a solid phase extraction-high performance liquid chromatographic method for the determination of eprosartan in human plasma. | Journal of chromatography. A 20060630 |
| Effect of eprosartan on the sympathetic response to cold pressor test in healthy volunteers. | Autonomic neuroscience : basic & clinical 20060630 |
| Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine? | Stroke 20060601 |
| Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. | American journal of physiology. Heart and circulatory physiology 20060401 |
| Effects of eprosartan on target organ protection. | Vascular health and risk management 20060301 |
| Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). | Stroke 20060201 |
| MOSES raises questions. | Stroke 20060201 |
| Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. | American journal of hypertension 20060201 |
| Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. | Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20060101 |
| [An AT-II blocker in patients with type II diabetes and arterial hypertension]. | Klinicheskaia meditsina 20060101 |
| Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine? | Nature clinical practice. Neurology 20060101 |
| [Effect of eprosartan on psychophysiological functions of drivers with arterial hypertension]. | Kardiologiia 20060101 |
| Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. | Diabetes 20051201 |
| Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. | American journal of physiology. Heart and circulatory physiology 20051001 |
| Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy? | Journal of hypertension 20051001 |
| Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress. | Journal of hypertension 20051001 |
| Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention. | Journal of clinical hypertension (Greenwich, Conn.) 20050801 |
| Adrenal angiotensin: origin and site of generation. | American journal of hypertension 20050801 |
| Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. | Journal of medicinal chemistry 20050630 |
| Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). | Stroke 20050601 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| [Effect of a combination of teveten and prestarium in patients with chronic heart failure]. | Georgian medical news 20050601 |
| Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients. | International journal of clinical practice 20050401 |
| Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia. | Clinical science (London, England : 1979) 20050201 |
| Losartan increases bradykinin levels in hypertensive humans. | Circulation 20050125 |
| Eprosartan (Teveten) offers new opportunities to prevent a second stroke. | Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20050101 |
| [Cerebral hemodynamics and endothelium function in patients with cerebrovascular pathology treated by teveten]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101 |
| Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. | American journal of nephrology 20050101 |
| Eprosartan: a review of its use in the management of hypertension. | Drugs 20050101 |
| Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. | The British journal of ophthalmology 20041201 |
| Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. | Blood pressure. Supplement 20041201 |
| Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. | Journal of the American Society of Nephrology : JASN 20041101 |
| New tools, old challenges: the emerging role of angiotensin receptor blockers in the treatment of the systolic hypertension epidemic. | The Canadian journal of cardiology 20041001 |
| Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting. | The Canadian journal of cardiology 20041001 |
| The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension. | The Canadian journal of cardiology 20041001 |
| The effect of treatment with eprosartan on pulse pressure: factors predicting response. | The Canadian journal of cardiology 20041001 |
| Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. | Journal of human hypertension 20040901 |
| Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. | American journal of hypertension 20040901 |
| Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. | Hypertension research : official journal of the Japanese Society of Hypertension 20040701 |
| A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension. | Japanese heart journal 20040701 |
| Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. | Circulation 20040504 |
| [Anti-hypertensive effect of eprosartan in diabetic patients]. | Anales de medicina interna (Madrid, Spain : 1984) 20040501 |
| Re: Heusser et al: elevation of sympathetic activity by eprosartan in young male subjects. | American journal of hypertension 20040301 |
| Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease. | Journal of hypertension 20040301 |
| Different prejunctional and postjunctional responses to angiotensin II and AT1-receptor inhibition: influence of maturation. | Journal of cardiovascular pharmacology 20040301 |
| Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta. | Cell stress & chaperones 20040301 |
| Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies. | Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20040101 |
| [Effect of eprosartan on microcirculation and blood rheology in patients with hypertensive disease]. | Kardiologiia 20040101 |
| [Comparison of eprosartan and captopril in left ventricular systolic dysfunction: relation of efficacy to myocardial viability]. | Kardiologiia 20040101 |
| [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. | Kardiologiia 20040101 |
| Eprosartan dual action offers clinical benefit for elderly and overweight hypertensives. | Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20040101 |
| Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. | Drugs under experimental and clinical research 20040101 |
| Teveten (eprosartan) reduces future risk in hypertensive stroke patients. | Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20040101 |
| [Elevation pressure in morning hours in patients with essential hypertension: effect therapy with eprosartan for leading stress tests]. | Kardiologiia 20040101 |
| Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension. | Journal of hypertension 20031201 |
| Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20031201 |
| [Dosage equivalents of AT1-receptor antagonists available in Germany]. | Deutsche medizinische Wochenschrift (1946) 20031031 |
| [Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology]. | Orvosi hetilap 20030907 |
| AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. | Autonomic neuroscience : basic & clinical 20030829 |
| Elevation of sympathetic activity by eprosartan in young male subjects. | American journal of hypertension 20030801 |
| [When the goal values are more than 20/10 mmHg distant. High blood pressure is to be forced down from two sides immediately]. | MMW Fortschritte der Medizin 20030710 |
| Cardiology patient page. Angiotensin receptor blockers. | Circulation 20030624 |
| Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. | Journal of medicinal chemistry 20030605 |
| Pre- and postsynaptic inhibitory potencies of the angiotensin AT1 receptor antagonists eprosartan and candesartan. | European journal of pharmacology 20030523 |
| Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. | Journal of medicinal chemistry 20030227 |
| Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. | Hypertension (Dallas, Tex. : 1979) 20030201 |
| Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress. | Kidney international 20030201 |
| Eprosartan for the treatment of hypertension. | Expert opinion on pharmacotherapy 20030101 |
| Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. | British journal of pharmacology 20030101 |
| [Neurocirculatory dystonia (does this disease exist?)]. | Kardiologiia 20030101 |
| [Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20030101 |
| Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. | The Canadian journal of cardiology 20021201 |
| Clinical profile of eprosartan. | Cardiovascular drugs and therapy 20021201 |
| Drug points: Dysgeusia and burning mouth syndrome by eprosartan. | BMJ (Clinical research ed.) 20021130 |
| Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery. | Journal of cardiovascular pharmacology 20020701 |
| Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. | American journal of hypertension 20020701 |
| [Therapy of hypertension. Why the systolic value is decisive]. | MMW Fortschritte der Medizin 20020606 |
| AT1 blockers and uric acid metabolism: are there relevant differences? | Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020601 |
| The clinical profile of the angiotensin II receptor blocker eprosartan. | Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020601 |
| [Irbesartan: a new possibility in the treatment of hypertension]. | Orvosi hetilap 20020526 |
| Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT1 antagonist. | Journal of pharmaceutical and biomedical analysis 20020401 |
| The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension. | The Journal of pharmacology and experimental therapeutics 20020401 |
| Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. | Kidney international 20020401 |
| Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). | The American journal of cardiology 20020315 |
| Brain angiotensinergic mediation of enhanced water consumption in lactating rats. | American journal of physiology. Regulatory, integrative and comparative physiology 20020301 |
| Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. | Journal of human hypertension 20020301 |
| Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists. | Electrophoresis 20020101 |
| [Significance of pharmacological blockade of angiotensin II type I receptors for correction of abnormal 24-hour blood pressure profile depending on its variability in patients with arterial hypertension stage II]. | Terapevticheskii arkhiv 20020101 |
| Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension. | Heart disease (Hagerstown, Md.) 20020101 |
| Safety and tolerability of eprosartan in combination with hydrochlorothiazide. | Drug safety 20020101 |
| [Policy of antihypertensive therapy in arterial hypertension in the elderly. II]. | Klinicheskaia meditsina 20020101 |
| [Effect of eprosartan on left ventricular diastolic function and cerebral hemodynamics in patients with hypertension]. | Kardiologiia 20020101 |
| [Metabolic effects of angiotensin-II receptor blockers]. | Kardiologiia 20020101 |
| Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. | Journal of hypertension 20011201 |
| Intrarenal angiotensin II: interstitial and cellular levels and site of production. | Kidney international 20011201 |
| Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension. | Journal of human hypertension 20011201 |
| Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo. | Journal of human hypertension 20011201 |
| Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. | American journal of hypertension 20011201 |
| Angiotensin II antagonists in systolic blood pressure control. | Hospital medicine (London, England : 1998) 20011201 |
| Differentiation in the angiotensin II receptor 1 blocker class on autonomic function. | Current hypertension reports 20010901 |
| Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure. | Current hypertension reports 20010901 |
| Issues in hypertension: drug tolerability and special populations. | American journal of hypertension 20010701 |
| Pharmacology and clinical efficacy of angiotensin receptor blockers. | American journal of hypertension 20010701 |
| Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. | Cardiovascular research 20010601 |
| Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists. | Bioorganic & medicinal chemistry 20010601 |
| [Antihypertensive drug. Dual action lowers blood pressure more effectively]. | MMW Fortschritte der Medizin 20010503 |
| ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. | American heart journal 20010501 |
| Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors. | Naunyn-Schmiedeberg's archives of pharmacology 20010501 |
| Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization. | Molecular pharmacology 20010401 |
| Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications. | Postgraduate medicine 20010401 |
| [Stress-induced hypertension. The work site--a cardiovascular risk]. | MMW Fortschritte der Medizin 20010315 |
| Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor? | Cleveland Clinic journal of medicine 20010301 |
| Subcellular localization of angiotensin II in kidney and adrenal. | Journal of hypertension 20010301 |
| Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain. | Pharmacological research 20010301 |
| [Angiotensin receptor blockers--significance for the therapy of hypertension]. | Wiener medizinische Wochenschrift (1946) 20010101 |
| Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. | Current medical research and opinion 20010101 |
| Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. | Blood pressure 20010101 |
| Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. | Blood pressure 19990101 |
| Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. | Journal of medicinal chemistry 19960202 |
| Characterization of [3H]SK&F 108566 as a radioligand for angiotensin type-1 receptor. | Journal of receptor research 19930101 |
| Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. | The Journal of pharmacology and experimental therapeutics 19920101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.